| B-Cell Malignant Neoplasm studied in …STUDIED_INderived200 of 7,465show all (up to 200) |
|---|
| → studied in | NCT00423644Phase 2 · completed A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01414855Phase 2 · completed A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01559935Phase 2 · completed Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03739814Phase 2 · recruiting Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | ALK-Positive Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228470Phase 2 · completed A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05354557Phase 2 · active not recruiting Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05621291NA · recruiting A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05952024Phase 2 · recruiting Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06055075Phase 1/Phase 2 · terminated A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179888Phase 2 · suspended Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06337318Phase 3 · recruiting Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Classic Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06738368Phase 2 · suspended Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06876142Phase 1/Phase 2 · suspended Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06977711Phase 1 · recruiting Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391657Phase 3 · recruiting A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07409246Phase 1 · recruiting A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07572136Phase 1 · recruiting Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07796373Phase 2 · not yet recruiting Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847957Phase 1/Phase 2 · not yet recruiting Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006518recruiting Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00923507recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01087294Phase 1 · completed Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01676805recruiting Tissue Collection for Studies of Lymph Cancer · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02473757enrolling by invitation Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03462719Phase 3 · active not recruiting A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03560752Phase 1 · active not recruiting CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181827Phase 3 · active not recruiting A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04269902Phase 3 · recruiting Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04973605Phase 1/Phase 2 · recruiting A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050097Phase 1 · active not recruiting A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05288062Phase 2 · terminated Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05421663Phase 1/Phase 2 · active not recruiting A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05424822Phase 1 · active not recruiting A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05874193Phase 2 · withdrawn A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05999877recruiting PICAROS - Acalabrutinib RWE on 1L CLL in Spain · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06073821Phase 3 · active not recruiting Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06124157Phase 2 · recruiting A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06252675Phase 2 · recruiting Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06421675Phase 2 · recruiting Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06425991Phase 1 · active not recruiting A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06454149recruiting Cohort Study for Gastric MALT Lymphoma · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06524375Phase 2 · active not recruiting A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06625203active not recruiting A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06697184Phase 1/Phase 2 · recruiting A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06742996Phase 3 · recruiting A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06846671Phase 3 · recruiting A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06943872Phase 3 · recruiting A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948084Phase 2 · recruiting Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973187Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07048353early Phase 1 · suspended CD30 CAR-T in the Treatment of CD30 Positive Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07277231Phase 3 · recruiting A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07439653Phase 1/Phase 2 · recruiting A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07660939Phase 1 · recruiting GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07685717Phase 2 · recruiting Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740317not yet recruiting Neurocognitive Trajectories After BCMA CAR-T · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01745588Phase 2 · completed Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02458014Phase 2 · completed Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02538198Phase 2 · active not recruiting Lenalidomide Maintenance in Plasma Cell Myeloma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02619682Phase 2 · completed Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02649387Phase 2 · completed Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03342144recruiting Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03349450Phase 2 · completed DPX-Survivac and Checkpoint Inhibitor in DLBCL · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03460977Phase 1 · recruiting A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03702309recruiting Liquid Biopsy Evaluation and Repository Development at Princess Margaret · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03779854Phase 2 · active not recruiting Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Burkitt Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108195Phase 1 · active not recruiting A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04133636Phase 2 · active not recruiting A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594642Phase 1 · active not recruiting A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04679012Phase 2 · active not recruiting Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04876248Phase 2 · active not recruiting Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923893Phase 3 · active not recruiting A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05023980Phase 3 · active not recruiting A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083169Phase 3 · active not recruiting A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05139017Phase 2/Phase 3 · recruiting A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05160584recruiting A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05201781Phase 4 · recruiting A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05438043Phase 3 · active not recruiting A Study of Daratumumab · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455320Phase 3 · active not recruiting A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552222Phase 3 · recruiting A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572229Phase 2 · active not recruiting Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05623020Phase 3 · recruiting A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05783596Phase 2 · active not recruiting Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05784441Phase 1 · active not recruiting A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05907759Phase 2 · recruiting Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05963074Phase 2 · active not recruiting A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06052826Phase 2 · recruiting Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06091865Phase 3 · recruiting A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06144606Phase 2 · recruiting Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06169215Phase 2 · active not recruiting Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208150Phase 3 · active not recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06284122Phase 3 · active not recruiting Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06299540recruiting Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06317662Phase 2 · recruiting Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06477783recruiting Study on the Clinical Efficacy of Teclistamab and Talquetamab · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06500884Phase 2 · recruiting A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06548152recruiting AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06550895Phase 2 · active not recruiting A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577025Phase 2 · active not recruiting A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06604715Phase 1 · active not recruiting A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06717347Phase 3 · recruiting A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06768489Phase 1 · recruiting A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788509Phase 1 · enrolling by invitation A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06820268Phase 1 · recruiting A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06910670NA · active not recruiting Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929624Phase 3 · active not recruiting A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030517Phase 4 · active not recruiting A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07073547Phase 1 · recruiting A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07149857Phase 2 · recruiting A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07172243recruiting BE.Amycon Biobank & Data Registry UZ Leuven · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07258511Phase 3 · recruiting A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07266441Phase 2 · active not recruiting A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07336472Phase 1/Phase 2 · recruiting A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518186Phase 3 · recruiting A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07519772Phase 1/Phase 2 · recruiting A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07570173Phase 2/Phase 3 · recruiting A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07602088recruiting A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07634471Phase 2/Phase 3 · recruiting A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07665450Phase 3 · recruiting A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07709000Phase 2 · not yet recruiting A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714044recruiting Rutgers University Study of the Genetics of Blood Cancers · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838714Phase 1 · recruiting Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07842198Phase 2 · not yet recruiting Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07842835not yet recruiting Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03986034Phase 2 · recruiting Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04728893Phase 2 · recruiting Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) · condition mapped PROBABILISTIC · 7,465 trials mapped (2,427 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840602Phase 2 · recruiting Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Lymphoplasmacytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552976Phase 3 · active not recruiting A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05947851Phase 3 · recruiting A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06136559Phase 3 · recruiting A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06213311Phase 2 · recruiting A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06398457early Phase 1 · recruiting Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06651970Phase 4 · recruiting Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07477587Phase 1 · recruiting A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07548450Phase 2 · not yet recruiting Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03463057Phase 2 · active not recruiting The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03993912Phase 3 · completed Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04662255Phase 3 · active not recruiting Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04732845Phase 1 · active not recruiting Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789303Phase 2 · recruiting Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06170671active not recruiting REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06175000Phase 2 · recruiting Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06553872Phase 2 · recruiting Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784167recruiting Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07116616Phase 1/Phase 2 · recruiting A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07783594Phase 2 · not yet recruiting Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00039676active not recruiting Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00339963completed Genome Expression in Lymphoma, Leukemia and Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00352924active not recruiting Agriculture Health Study · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01087333recruiting Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Hairy Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02537613Phase 1 · active not recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02693535Phase 2 · recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03226704enrolling by invitation Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03628612Phase 2 · enrolling by invitation Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231629Phase 2 · active not recruiting Sequential Therapy in Multiple Myeloma Guided by MRD Assessments · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05376345Phase 1 · completed BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05471843Phase 1/Phase 2 · active not recruiting Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05861050Phase 1/Phase 2 · suspended Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Blastoid Variant Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06103838Phase 2 · recruiting 18F-Fluciclovine PET/CT in Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465316Phase 1 · recruiting Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07095452Phase 2/Phase 3 · recruiting A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218341Phase 4 · recruiting A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226843Phase 1 · recruiting A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833046not yet recruiting Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01829958NA · active not recruiting Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02003222Phase 3 · active not recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03909412Phase 1 · recruiting Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04096066Phase 3 · active not recruiting A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04523428Phase 2 · recruiting REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661137Phase 2 · recruiting A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04920084NA · active not recruiting A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Monoclonal Gammopathy of Undetermined Significance | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04935684Phase 2 · recruiting Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05296070Phase 2 · recruiting Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029309Phase 1/Phase 2 · recruiting Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,465 trials mapped (2,427 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06474182NA · recruiting Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06549595Phase 3 · recruiting A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06997081Phase 2 · recruiting ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07096778Phase 2 · recruiting Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07802717Phase 1 · recruiting A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830238early Phase 1 · not yet recruiting SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 7,465 trials mapped (2,427 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830485Phase 2 · not yet recruiting CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 7,465 trials mapped (2,427 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |